黑龙江省肿瘤登记地区2015年肝癌发病与死亡分析

肝癌电子杂志 ›› 2020, Vol. 7 ›› Issue (2): 12-15.

黑龙江省肿瘤登记地区2015年肝癌发病与死亡分析

孙惠昕^1,2,3,*, 王婉莹³, 张茂祥^1,2,3, 贾海晗³, 宋冰冰^1,2,3

1 哈尔滨医科大学肿瘤防治研究所,黑龙江哈尔滨 150081;
2 黑龙江省医学科学院,黑龙江哈尔滨 150081;
3 黑龙江省癌症中心,黑龙江哈尔滨150081

收稿日期:2020-05-06 出版日期:2020-06-30 发布日期:2020-07-23
通讯作者: ^* 孙惠昕 E-mail: 6666901@163.com
作者简介:孙惠昕, 硕士研究生,哈尔滨医科大学肿瘤防治研究所。
基金资助:
黑龙江省卫生健康委员会科研课题（2017-199）

Analysis of morbidity and mortality of liver cancer in Heilongjiang province, 2015

Sun Huixin^1,2,3,*, Wang Wanying³, Zhang Maoxiang^1,2,3, Jia Haihan³, Song Bingbing^1,2

1 Institute of Cancer Prevention and Treatment, Harbin Medical University, Harbin 150081, Heilongjiang, China;
2 Heilongjiang Academy of Medical Science, Harbin 150081,Heilongjiang, China;
3 Heilongjiang Cancer Center, Harbin 150081, Heilongjiang, China

Received:2020-05-06 Online:2020-06-30 Published:2020-07-23

摘要/Abstract

摘要： 目的: 分析黑龙江省肿瘤登记地区2015年肝癌的发病和死亡情况。方法: 经过质量审核后,7个肿瘤登记处数据被纳入分析,按照地区（城乡）、性别分层计算肝癌发病率、死亡率,采用2000年中国标准人口和SEGI世界标准人口结构分别计算中国人口和世界人口年龄标化发病/死亡率。结果: 黑龙江省肿瘤登记地区肝癌死亡发病比为0.92,病理诊断率(MV%)为50.73%,死亡补发病比例为3.21%。黑龙江省肿瘤登记地区2015年肝癌发病粗率为27.44/10万（男性40.30/10万,女性14.75/10万）,中国人口标化率为16.31/10万,世界人口标化率为16.08/10万;城市地区发病粗率为24.74/10万,中国人口标化率为13.87/10万;农村地区发病粗率为35.27/10万,中国人口标化率为24.95/10万。黑龙江省肿瘤登记地区2015年肝癌死亡粗率为25.20/10万（男性37.03/10万,女性13.51/10万）,中国人口标化率为14.87/10万,世界人口标化率为14.75/10万;城市地区死亡粗率为23.18/10万,中国人口标化率为12.85/10万;农村地区死亡粗率为31.05/10万,中国人口标化率为21.96/10万。结论: 必须将农村人口以及男性作为肝癌防治的重点对象,推进肝癌早诊早治以及肝癌的机会性筛查,提高早期肝癌的检出率,减少肝癌的发病与死亡造成的疾病负担。

关键词: 发病率, 死亡率, 肝癌

Abstract: Objective: To analyze the morbidity and mortality of liver cancer in the cancer registries in Heilongjiang province in 2015.Methods: Incidence rate and gender of liver cancer were calculated by 7 tumor registry data. The morbidity and mortality of liver cancer were calculated according to the stratification of the area (urban and rural) and gender. The age standardized morbidity / mortality of China's population and world population were calculated by the 2000 Chinese population and SEGI world population constitution.Results: The morphology verified cases (MV%) accounted for 50.73% and 3.21% of incident cases were identified through death certifications only (DCO%) with a mortality to incidence ratio(M/I) of 0.92. In the cancer registries in Heilongjiang province, incidence of liver cancer in 2015 was 27.44/100 000 (male 40.30/100 000, female 14.75/100 000), China's population standardized rate was 16.31/100 000, the world's population standardized rate was 16.08/100 000; the incidence in urban areas was 24.74/100 000, China's population standardized rate was 13.87/100 000; the incidence in rural areas was 35.27/100 000, China's population standardized rate was 24.95/100 000. In the cancer registration area of Heilongjiang Province, the crude death rate of liver cancer in 2015 was 25.20/100 000 (male 37.03/100 000, female 13.51/100 000), the population standardized rate of China was 14.87/100 000, the world population standardized rate was 14.75/100 000; the crude death rate of urban area was 23.18/100 000, the population standardized rate of China was 12.85/100 000; the crude death rate of rural area was 31.05/100 000, the population standardized rate of China was 21.96/100 000.Conclusion: Rural population and the male should be the focus of the prevention and treatment of liver cancer, so as to promote the early diagnosis and treatment of liver cancer and the opportunistic screening of liver cancer, improve the detection rate of early liver cancer, and reduce the disease burden caused by the incidence and death of liver cancer.

Key words: Morbidity, Mortality, Liver cancer

孙惠昕, 王婉莹, 张茂祥, 贾海晗, 宋冰冰. 黑龙江省肿瘤登记地区2015年肝癌发病与死亡分析[J]. 肝癌电子杂志, 2020, 7(2): 12-15.

Sun Huixin, Wang Wanying, Zhang Maoxiang, Jia Haihan, Song Bingbing. Analysis of morbidity and mortality of liver cancer in Heilongjiang province, 2015[J]. Electronic Journal of Liver Tumor, 2020, 7(2): 12-15.

参考文献

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] SUN HX, SONG BB, ZHANG MX.Analysis of cancer incidence and mortality data in Heilongjiang province cancer registries, China, 2015[J]. Oncology and Translational Medicine, 2019, 5(4):182-187.
[3] 孙可欣, 郑荣寿, 张思维, 等. 2015年中国分地区恶性肿瘤发病和死亡分析[J].中国肿瘤, 2019, 28(1):1-11.
[4] 国家癌症中心. 中国肿瘤登记工作指导手册(2016)[M]. 北京:人民卫生出版社, 2016:73-75.
[5] BRAY F, MAX PARKIN D.Evaluation of data quality in the cancer registry: principles and methods. Part Ⅰ: Comparability, Validity and Timeliness[J]. Eur J Cancer, 2009, 45(5):747-755.
[6] LONDON WT, PETRICK JL, MCGLYNN KA.Cancer epidemiology and prevention[M]. New York: Oxford University Press, 2018:635-660.
[7] WU J, YANG SG, XU KJ, et al.Patterns and trends of liver cancer incidence rates in eastern and southeastern asian countries (1983~2007) and predictions to 2030[J]. Gastroenterology, 2018 , 154(6):1719-1728.
[8] ZENG HM, ZHENG RS, GUO YM, et al.Cancer survival in China, 2003~2005: A population-based study[J]. Int J Cancer, 2015, 136(8):1921-1930.
[9] 孙惠昕, 陈王洋, 张茂祥, 等. 2013年黑龙江省肿瘤登记地区恶性肿瘤发病死亡分析[J]. 国际肿瘤学杂志, 2017, 44(11):828-833.
[10] 孙惠昕, 陈王洋, 张茂祥, 等. 2014年黑龙江省肿瘤登记地区恶性肿瘤发病死亡分析[J]. 中华肿瘤防治杂志, 2018, 25(20):1407-1412.
[11] 孙坤, 王冲, 沈成凤,等. 2015年天津市恶性肿瘤流行情况分析[J]. 实用肿瘤学杂志, 2020, 34(2):114-119.
[12] 鲍萍萍, 吴春晓, 张敏璐, 等. 2015年上海市恶性肿瘤流行特征分析[J]. 中国癌症杂志, 2019, 29(2):81-99.
[13] 陈琼, 刘曙正, 全培良, 等. 2015年河南省恶性肿瘤发病与死亡情况分析[J]. 河南医学研究, 2019, 28(8):1345-1351.
[14] YAMASHITA T, KANEKO S.Liver Cancer[J]. Rinsho Byori, 2016, 64(7):787-796.
[15] MARENGO A, ROSSO C, BUGIANESI E.Liver cancer: connections with obesity, fatty liver, and cirrhosis[J]. Annu Rev Med, 2016, 67:103-117.
[16] THURSZ M, FONTANET A.HCV transmission in industrialized countries and resource-constrained areas[J]. Nat Rev Gastroenterol Hepatol, 2014, 11(1):28-35.
[17] 张茂祥, 孙惠昕, 宋冰冰. 2008-2012年哈尔滨市道里区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2019, 33(3): 261-265.